266 related articles for article (PubMed ID: 35787253)
1. Induction therapy and outcome of proliferative lupus nephritis in the top end of Northern Australia - a single centre study retrospective study.
Xu C; Goh KL; Abeyaratne A; Priyadarshana K
BMC Nephrol; 2022 Jul; 23(1):235. PubMed ID: 35787253
[TBL] [Abstract][Full Text] [Related]
2. Presentation and outcome of pediatric lupus nephritis from a large single centre contemporary cohort in Eastern India.
Biswas D; Dasgupta D; Pal P; Sinha R
Lupus; 2023 Oct; 32(12):1440-1446. PubMed ID: 37707867
[TBL] [Abstract][Full Text] [Related]
3. Real-World Experience of Safety of Mycophenolate Mofetil in 119 Japanese Patients with Systemic Lupus Erythematosus: A Retrospective Single-Center Study.
Abe Y; Tada K; Yamaji K; Tamura N
Biomed Res Int; 2021; 2021():8630596. PubMed ID: 33564682
[TBL] [Abstract][Full Text] [Related]
4. Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV.
Hanaoka H; Yamada H; Kiyokawa T; Iida H; Suzuki T; Yamasaki Y; Ooka S; Nagafuchi H; Okazaki T; Ichikawa D; Shirai S; Shibagaki Y; Koike J; Ozaki S
Arthritis Res Ther; 2017 Jan; 19(1):4. PubMed ID: 28086993
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases.
Kasitanon N; Petri M; Haas M; Magder LS; Fine DM
Lupus; 2008 Jan; 17(1):40-5. PubMed ID: 18089682
[TBL] [Abstract][Full Text] [Related]
6. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
8. Variations in clinical presentation and biomarkers among biopsy-proven lupus nephritis patients: a Top End retrospective cohort study.
Xu C; Goh KL; Abeyaratne A; Mogulla M; Majoni W; Priyadarshana K
Intern Med J; 2023 Apr; 53(4):531-539. PubMed ID: 34697868
[TBL] [Abstract][Full Text] [Related]
9. The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis.
Nossent J; Raymond W; Kang A; Wong D; Ognjenovic M; Chakera A
Lupus; 2018 Oct; 27(11):1838-1846. PubMed ID: 30092734
[TBL] [Abstract][Full Text] [Related]
10. Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Hailu GT; Hussen SU; Getachew S; Berha AB
BMC Nephrol; 2022 Jun; 23(1):214. PubMed ID: 35715762
[TBL] [Abstract][Full Text] [Related]
11. Treatment for lupus nephritis.
Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
[TBL] [Abstract][Full Text] [Related]
12. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
F L; Y T; X P; L W; H W; Z S; H Z; Z H;
Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
[TBL] [Abstract][Full Text] [Related]
13. Childhood Systemic Lupus Erythematosus: Presentation, management and long-term outcomes in an Australian cohort.
Cann MP; Sage AM; McKinnon E; Lee SJ; Tunbridge D; Larkins NG; Murray KJ
Lupus; 2022 Feb; 31(2):246-255. PubMed ID: 35037500
[TBL] [Abstract][Full Text] [Related]
14. Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.
Almalki AH; Alrowaie FA; Alhozali HM; Almalki NK; Alsubei AI; Alturki MS; Sadagah LF
Lupus; 2019 Aug; 28(9):1082-1090. PubMed ID: 31296138
[TBL] [Abstract][Full Text] [Related]
15. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
Condon MB; Ashby D; Pepper RJ; Cook HT; Levy JB; Griffith M; Cairns TD; Lightstone L
Ann Rheum Dis; 2013 Aug; 72(8):1280-6. PubMed ID: 23740227
[TBL] [Abstract][Full Text] [Related]
16. The value of early renal biopsy in systemic lupus erythematosus patients presenting with renal involvement.
Hsieh YP; Wen YK; Chen ML
Clin Nephrol; 2012 Jan; 77(1):18-24. PubMed ID: 22185964
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
Lanata CM; Mahmood T; Fine DM; Petri M
Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes in refractory lupus nephritis: Data from an observational study.
Gururani S; Devarasetti PK; Uppin M; Rajasekhar L
Lupus; 2021 Oct; 30(11):1725-1731. PubMed ID: 34304627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
